Enanta Pharmaceuticals, Inc. (ENTA) News
Follow Enanta Pharmaceuticals, Inc. (ENTA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Enanta Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:55 AM UTC
L
HC Wainwright & Co. reiterates Buy rating on Enanta Pharma, $20 price target
HC Wainwright & Co. reiterated their Buy rating on Enanta Pharma's stock with a price target of $20.00.The price target implies an upside of 61.0% from the Sep 22 close of $12.42.Key takeaways from the analyst noteStrong
EQUITY | Sep 23, 2026, 10:44 AM UTC
L
ENTA - Enanta Pharmaceuticals to Participate in September Investor Conferences
ENTA - Enanta Pharmaceuticals to Participate in September Investor Conferences
EQUITY | Sep 01, 2026, 11:04 AM UTC
L
Enanta management to participate in two September investor conferences
Enanta Pharmaceuticals said members of management will participate in two investor conferences in September, with live webcasts of each conference.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Enanta Enters $75 Million At-the-Market Stock Offering Agreement
() -- Enanta Pharmaceuticals (ENTA) said Thursday it entered into an at-the-market offering agreement under which it may offer and sell up to $75 million of its common stock from time to time. The company said it has no
EQUITY | Jul 02, 2026, 09:26 PM UTC
L
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
SEC Filing
REGULATION | Jul 02, 2026, 08:58 PM UTC
L
Enanta Appeals Paxlovid Suit
Enanta files notice of appeal in Paxlovid lawsuit against Pfizer
EQUITY | Jun 23, 2026, 09:36 PM UTC
H
ENTA: AbbVie Gets EU Approval
Enanta Pharmaceuticals' partner AbbVie receives European Commission approval of MAVIRET for people with acute Hepatitis C Virus
EQUITY | Jun 23, 2026, 09:23 AM UTC